Informações
Data: 15/04/2013 – 08:30:00
Fim: 15/04/2013 – 17:00:00
Onde: CNPEM – Rua Giuseppe Máximo Scolfaro, 10.000 – Campinas, SÃO PAULO 13280000 Brazil – Telefone: 19 35121267
Detalhes
We have developed several approaches based on different biophysical methods to identify low affinity fragments binding to macromolecules. These fragments act as starting points for subsequent elaboration into more potent ligands. Examples of our approach will include development of inhibitors again enzymes from Mycobacterium tuberculosis. The talk will also mention recent progress targetting protein-protein interactions and also riboswitches.
Professor Chris Abell – FMedSci, Department of Chemistry, University of Cambridge
15th April – 8:30 am
LNBio – Room 69
Campus – Centro Nacional de Pesquisa em Energia e Materiais – CNPEM
Giuseppe M. Scolfaro, 10.000 – Guará
Phone: (19) 3512-1010
Chris Abell is the Professor of Biological Chemistry at the University of Cambridge, and the Todd Hamied Fellow at Christ’s College, Cambridge. He was an undergraduate and graduate at Cambridge, and did a postdoc with Professor David Cane at Brown University. Chris leads a multidisciplinary group interested in biological and synthetic chemistry. A major focus is on the use of fragment-based approaches to find inhibitors of enzymes from M. tuberculosis and small molecules that disrupt protein-protein interactions. In 1999 he co-founded Astex. Since 2011 Astex Pharmaceuticals has been on the Nasdaq and in 2012 had 7 compounds in clinical trials. It is recognised as world-leading in the area of fragment-based drug discovery. Chris also has major interests in the use of microdroplets to study biological reactions, and in 2010 co-founded Sphere Fluidics. He holds positions on various scientific advisory boards and was a founding director of Cambridge Enterprise
